Willow Biosciences Inc. (C:WLLW)
Business Focus: Biopharmaceuticals
Mar 28, 2024 07:30 pm ET
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
Completed the reorganization of the Company during 2023 with all lab operations now located in the Sunnyvale, California
Mar 28, 2024 07:30 pm ET
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
Completed the reorganization of the Company during 2023 with all lab operations now located in the Sunnyvale, California
Feb 29, 2024 05:00 pm ET
WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC
CALGARY, AB, Feb. 29, 2024 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce a second strategic investment (the "Milestone Investment"), by way of non-brokered private placement, from Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, for the continued development of natu
Feb 20, 2024 05:00 pm ET
WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS
Investment further validates Willow's technology for the development and sustainable manufacture of natural ingredients
Feb 20, 2024 05:00 pm ET
WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS
Investment further validates Willow's technology for the development and sustainable manufacture of natural ingredients
Jan 31, 2024 06:00 am ET
WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
SUNNYVALE, Calif., Jan. 31, 2024 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, today announced a collaboration with a leading Active Pharmaceutical Ingredient ("API") manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest product sold globally.
Jan 31, 2024 06:00 am ET
WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
SUNNYVALE, Calif., Jan. 31, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, today announced a collaboration with a leading Active Pharmaceutical Ingredient ("API") manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest product sold globally.
Jan 16, 2024 06:00 am ET
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
SUNNYVALE, Calif., Jan. 16, 2024 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, today announced a collaboration with Enterin, Inc. ("Enterin"), a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic disorders, to develop new sustainable manufacturing routes to their key intermediates and active pharmaceutical ingredients (APIs).
Jan 16, 2024 06:00 am ET
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
SUNNYVALE, Calif., Jan. 16, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, today announced a collaboration with Enterin, Inc. ("Enterin"), a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic disorders, to develop new sustainable manufacturing routes to their key intermediates and active pharmaceutical ingredients (APIs).
Jan 10, 2024 06:00 am ET
WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023
Estimated FY 2023 revenues in excess of $1.3 million is a record year for the Company
Jan 10, 2024 06:00 am ET
WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023
Estimated FY 2023 revenues in excess of $1.3 million is a record year for the Company
Dec 11, 2023 11:16 am ET
Willow Bioscience plans to advance development program with Nasdaq-listed company
Willow Bioscience CEO Dr Chris Savile
joined Steve Darling from Proactive to share a significant
development. The company has unveiled a noteworthy partnership with a
Nasdaq-listed biopharmaceutical company, with a shared objective of
forging precise and efficient manufacturing pathways for advanced
intermediates and high-value active pharmaceutical ingredients (APIs).
Dec 07, 2023 06:00 am ET
WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
Program brings immediate R&D revenue and first commercial supply revenue as early as 2024
Dec 07, 2023 06:00 am ET
WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
Program brings immediate R&D revenue and first commercial supply revenue as early as 2024
Nov 14, 2023 05:06 pm ET
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Record revenues for the third quarter and the nine months ended September 30, 2023
Nov 14, 2023 05:06 pm ET
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Record revenues for the third quarter and the nine months ended September 30, 2023
Oct 10, 2023 07:52 pm ET
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING
CALGARY, AB, Oct. 10, 2023 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce the completion of its previously announced offering of convertible debenture units of the Company (the "Debenture Units"), on a non-brokered private placement basis, for aggregate proceeds of C$800,000 (the "Offering"). The Offering was led by insiders including members of the Board of Directors and members of the
Oct 10, 2023 07:52 pm ET
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING
CALGARY, AB, Oct. 10, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce the completion of its previously announced offering of convertible debenture units of the Company (the "Debenture Units"), on a non-brokered private placement basis, for aggregate proceeds of C$800,000 (the "Offering"). The Offering was led by insiders including members of the Board of Directors and members
Oct 05, 2023 10:41 am ET
Willow Bioscience teams again with Suanfarma on large volume anti-infective API
Willow Bioscience CEO Dr Chris Savile
joined Steve Darling from Proactive to announce a significant
collaboration agreement between Willow Biosciences and
Suanfarma.
Oct 03, 2023 07:00 am ET
WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION
SUNNYVALE, Calif., Oct. 3, 2023 /CNW/ - Willow Biosciences Inc., ("Willow") (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient ("API") through precision fermentation. Through the partnership, SUANFARMA will have access to Willow's proprietary strain optimization technologies to develop a more cost-effective production process.
Oct 03, 2023 07:00 am ET
WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION
SUNNYVALE, Calif., Oct. 3, 2023 /PRNewswire/ - Willow Biosciences Inc., ("Willow") (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient ("API") through precision fermentation. Through the partnership, SUANFARMA will have access to Willow's proprietary strain optimization technologies to develop a more cost-effective production process.
Sep 12, 2023 11:39 am ET
Willow Bioscience eyes another use for BioOxi platform with R&D of ursodeoxycholic acid
Willow Bioscience CEO Dr Chris Savile
joined Steve Darling from Proactive to announce some significant
developments within the company.
Sep 12, 2023 07:00 am ET
WILLOW BIOSCIENCES ANNOUNCES COMPANY INSIDER LED CONVERTIBLE DEBENTURE FINANCING
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW/
Sep 06, 2023 07:00 am ET
WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA
Company's BioOxi™ Platform solves for selective C-H hydroxylation, one of the "Holy Grails" of chemistry
Sep 04, 2023 11:31 am ET
Willow Bioscience files patent to help reduce costs of corticosteroids
Willow Bioscience CEO Dr Chris Savile
joined Steve Darling from Proactive to announce a groundbreaking
development in the pharmaceutical industry.
Aug 30, 2023 07:00 am ET
WILLOW ANNOUNCES FILING OF PATENT APPLICATION FOR PROCESS TO PRODUCE CORTICOSTEROIDS AT SIGNFICANTLY REDUCED COST
Company's BioOxi™-based process reduces number of steps and associated costs of corticosteroids manufacturing by up to two-thirds
Aug 29, 2023 11:39 am ET
Willow Bioscience shifts focus to opportunity with BioOxi bio-oxidation platform
Willow Bioscience CEO Dr Chris Savile
joined Steve Darling from Proactive to share news the company has
embarked on a major strategic shift, focusing its commercial efforts
on the BioOxi platform. To assist in this transition, Willow
Biosciences has engaged an advisor to explore and evaluate potential
opportunities.
Aug 24, 2023 07:00 am ET
WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM
Announces commercial focus on BioOxiTM bio-oxidation platform as part of targeted alignment on nearer-term and larger revenue opportunities
Aug 21, 2023 07:00 am ET
WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
SUNNYVALE, Calif., Aug. 21, 2023 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, today announced a collaboration with a Nasdaq-listed biopharma company to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients (APIs).
Aug 08, 2023 05:10 pm ET
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
New partnerships and contracts expected to bring in over $1 million in near-term R&D/milestone revenue and generate long term commercial revenue
Aug 02, 2023 07:00 am ET
WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON AUGUST 9
President and CEO Dr. Chris Savile to provide business update at event open to all investors
Aug 02, 2023 07:00 am ET
WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON AUGUST 9
President and CEO Dr. Chris Savile to provide business update at event open to all investors
Jul 20, 2023 07:00 am ET
WILLOW AND KALSEC ADVANCE DEVELOPMENT PROGRAM FOR NEW NATURAL FUNCTIONAL INGREDIENT FOR SAVORY FOODS
Program further validates Willow's technology and focus on commercial execution and aligns with its strategic focus on near term revenue generation
Jul 20, 2023 07:00 am ET
WILLOW AND KALSEC ADVANCE DEVELOPMENT PROGRAM FOR NEW NATURAL FUNCTIONAL INGREDIENT FOR SAVORY FOODS
Program further validates Willow's technology and focus on commercial execution and aligns with its strategic focus on near term revenue generation
Jun 07, 2023 07:00 am ET
WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON JUNE 14
President and CEO Dr. Chris Savile to provide business update at event open to all investors
Jun 07, 2023 07:00 am ET
WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON JUNE 14
President and CEO Dr. Chris Savile to provide business update at event open to all investors
Jun 02, 2023 09:51 am ET
Willow Bioscience agrees to partnership with biotech company looking at age-related diseases
Willow Bioscience CEO Dr Chris Savile
joined Steve Darling from Proactive to share news the company has
agreed to a Master Services Agreement with an innovative biotech
company with the focus on age-related diseases. This partnership will
see the company develop precision fermentation processes for a class
of molecules to develop novel solutions for age-related diseases.
May 31, 2023 07:00 am ET
WILLOW SIGNS MASTER SERVICES AGREEMENT WITH INNOVATIVE BIOTECH COMPANY TO DEVELOP INGREDIENTS FOR AGE-RELATED DISEASES
Biotech partner recognizes strength of Willow's first in class FutureGrown™ technology platform for producing natural products
May 31, 2023 07:00 am ET
WILLOW SIGNS MASTER SERVICES AGREEMENT WITH INNOVATIVE BIOTECH COMPANY TO DEVELOP INGREDIENTS FOR AGE-RELATED DISEASES
Biotech partner recognizes strength of Willow's first in class FutureGrown™ technology platform for producing natural products
May 23, 2023 07:00 am ET
KALSEC AND WILLOW BIOSCIENCES TO DEVELOP NOVEL ENZYME FOR PRODUCTION OF AN ADVANCED BEVERAGE INGREDIENT
Rapid success of first collaboration leads to partnership on high-value specialty ingredient
May 23, 2023 07:00 am ET
KALSEC AND WILLOW BIOSCIENCES TO DEVELOP NOVEL ENZYME FOR PRODUCTION OF AN ADVANCED BEVERAGE INGREDIENT
Rapid success of first collaboration leads to partnership on high-value specialty ingredient
May 12, 2023 05:04 pm ET
WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
MOUNTAIN VIEW, Calif., May 12, 2023 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on May 12, 2023 (the "Meeting"). A total of 57,318,575 common shares, representing approximately 46.329% of the Company's issued and outstanding shares were represented at the meeting.
May 11, 2023 08:58 pm ET
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2023 RESULTS
Starts off year with significant commercial momentum toward focus on delivering robust year-over-year revenue growth for 2023
May 11, 2023 08:58 pm ET
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2023 RESULTS
Starts off year with significant commercial momentum toward focus on delivering robust year-over-year revenue growth for 2023
Apr 18, 2023 04:30 pm ET
WILLOW ANNOUNCES COMMERCIAL AGREEMENT WITH SANDHILL ONE
Commercial agreement follows the early success on the development phase of the UDCA program with Sandhill One
Apr 18, 2023 04:30 pm ET
WILLOW ANNOUNCES COMMERCIAL AGREEMENT WITH SANDHILL ONE
Commercial agreement follows the early success on the development phase of the UDCA program with Sandhill One
Apr 12, 2023 04:30 pm ET
WILLOW ANNOUNCES ROLLOUT OF BioOxi PLATFORM PROVIDING VALUABLE AND EXPEDITED BIOCONVERSION-ENABLED CHEMICAL MANUFACTURING
Complements Company's significant expertise in existing strain engineering and precision fermentation
Apr 12, 2023 04:30 pm ET
WILLOW ANNOUNCES ROLLOUT OF BioOxi PLATFORM PROVIDING VALUABLE AND EXPEDITED BIOCONVERSION-ENABLED CHEMICAL MANUFACTURING
Complements Company's significant expertise in existing strain engineering and precision fermentation
Mar 28, 2023 04:10 pm ET
WILLOW BIOSCIENCES ANNOUNCES CHANGES TO BOARD AND MANAGEMENT
Willow Continues its Transition to the Bay Area in California with Management Promotions and a New Board Member
Mar 28, 2023 04:10 pm ET
WILLOW BIOSCIENCES ANNOUNCES CHANGES TO BOARD AND MANAGEMENT
Willow Continues its Transition to the Bay Area in California with Management Promotions and a New Board Member
Mar 22, 2023 07:00 am ET
WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY
CALGARY, AB and MOUNTAIN VIEW, Calif., March 22, 2023 /CNW/ - WILLOW BIOSCIENCES, (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced that they have, together with SUANFARMA's CIPAN manufacturing site, completed the development and manufacturing process in pilot scale for the WILLOW-owned ingredient, Cannabigerol (CBG). The 36 m3 scaling-up production batches required for the forthcoming qualification and registration will be completed during 2023.
Mar 22, 2023 07:00 am ET
WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY
CALGARY, AB and MOUNTAIN VIEW, Calif., March 22, 2023 /PRNewswire/ - WILLOW BIOSCIENCES, (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced that they have, together with SUANFARMA's CIPAN manufacturing site, completed the development and manufacturing process in pilot scale for the WILLOW-owned ingredient, Cannabigerol (CBG). The 36 m3 scaling-up production batches required for the forthcoming qualification and registration will be completed during 2023.
Mar 21, 2023 06:49 pm ET
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIALS AND OPERATIONS AND FILING OF ITS 2022 AIF
Reports Highest Quarterly and Annual Revenue in Company History with Significant Year-Over-Year Growth Expected for 2023
Feb 22, 2023 06:00 am ET
WILLOW ANNOUNCES APPOINTMENT OF DR. JIM LALONDE TO BOARD OF DIRECTORS
Dr. Lalonde has pioneered key advancements in enzyme engineering and biocatalysis that has revolutionized chemical production, protein engineering for food and nutrition, as well as drug discovery and development leading to new routes to pharmaceutical actives behind blockbuster drugs
Jan 17, 2023 06:00 am ET
WILLOW ANNOUNCES FOLLOW-ON ENGAGEMENT FOR NEXT PHASE OF PARTNERED PHARMACEUTICAL PROJECT
Represents early progress against targeted milestones anticipated for 2023 to expand company growth
Jan 17, 2023 06:00 am ET
WILLOW ANNOUNCES FOLLOW-ON ENGAGEMENT FOR NEXT PHASE OF PARTNERED PHARMACEUTICAL PROJECT
Represents early progress against targeted milestones anticipated for 2023 to expand company growth
Dec 14, 2022 06:00 am ET
WILLOW PROVIDES CORPORATE UPDATES, BUSINESS OUTLOOK AND KEY TARGETED MILESTONES ANTICIPATED FOR 2023 TO EXPAND GROWTH
CALGARY, AB AND MOUNTAIN VIEW, Calif., Dec. 14, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today a recap of key milestones the Company has successfully achieved in 2022, as well as its business outlook and key targeted milestones anticipated for 2023 to expand growth.
Dec 14, 2022 06:00 am ET
WILLOW PROVIDES CORPORATE UPDATES, BUSINESS OUTLOOK AND KEY TARGETED MILESTONES ANTICIPATED FOR 2023 TO EXPAND GROWTH
CALGARY, AB AND MOUNTAIN VIEW, Calif., Dec. 14, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today a recap of key milestones the Company has successfully achieved in 2022, as well as its business outlook and key targeted milestones anticipated for 2023 to expand growth.
Dec 07, 2022 06:00 am ET
WILLOW FURTHER OPTIMIZES ITS BUSINESS TO FOCUS ON NEAR-TERM REVENUE GENERATION AND REDUCE CASH BURN
CALGARY, AB and MOUNTAIN VIEW, Calif, Dec. 7, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today that it has taken additional steps to focus on near-term revenue generation, protect its balance sheet and reduce its cash burn.
Dec 07, 2022 06:00 am ET
WILLOW FURTHER OPTIMIZES ITS BUSINESS TO FOCUS ON NEAR-TERM REVENUE GENERATION AND REDUCE CASH BURN
CALGARY, AB and MOUNTAIN VIEW, Calif, Dec. 7, 2022 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today that it has taken additional steps to focus on near-term revenue generation, protect its balance sheet and reduce its cash burn.
Nov 08, 2022 06:00 am ET
KALSEC SIGNS MASTER SERVICES AGREEMENT WITH WILLOW BIOSCIENCES FOR THE DEVELOPMENT AND MANUFACTURE OF FUNCTIONAL FOOD INGREDIENTS USING PRECISION FERMENTATION
KALAMAZOO, Mich. and CALGARY, AB and MOUNTAIN VIEW, Calif., Nov. 8, 2022 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients and Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, announce entry into a Master Services Agreement (the "MSA") to develop and commercialize a precision fermentation production process for
Nov 08, 2022 06:00 am ET
KALSEC SIGNS MASTER SERVICES AGREEMENT WITH WILLOW BIOSCIENCES FOR THE DEVELOPMENT AND MANUFACTURE OF FUNCTIONAL FOOD INGREDIENTS USING PRECISION FERMENTATION
KALAMAZOO, Mich. and CALGARY, AB and MOUNTAIN VIEW, Calif., Nov. 8, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients and Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, announce entry into a Master Services Agreement (the "MSA") to develop and commercialize a precision fermentation production proc
Nov 07, 2022 06:00 am ET
WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST
CALGARY, AB AND MOUNTAIN VIEW, Calif, Nov. 7, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today announced that it will host a webcast investor presentation on Thursday, November 10th at 2:00 PM EST.
Nov 07, 2022 06:00 am ET
WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST
CALGARY, AB AND MOUNTAIN VIEW, Calif, Nov. 7, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today announced that it will host a webcast investor presentation on Thursday, November 10th at 2:00 PM EST.
Nov 03, 2022 07:18 pm ET
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2022 RESULTS AND ANNOUNCES APPOINTMENT OF DR SEUFER-WASSERTHAL AS PRESIDENT AND CEO
CALGARY, AB AND MOUNTAIN VIEW, CA, Nov. 3, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, has released its financial and operating results for the three and nine months ended September 30, 2022, reporting significant progress to its operational platform, leadership and strong liquidity. Additionally, Willow has announced today that its Board of Directors has appointed Dr. Peter Seufer-Wasserthal as its P
Nov 03, 2022 07:18 pm ET
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2022 RESULTS AND ANNOUNCES APPOINTMENT OF DR SEUFER-WASSERTHAL AS PRESIDENT AND CEO
CALGARY, AB AND MOUNTAIN VIEW, CA, Nov. 3, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, has released its financial and operating results for the three and nine months ended September 30, 2022, reporting significant progress to its operational platform, leadership and strong liquidity. Additionally, Willow has announced today that its Board of Directors has appointed Dr. Peter Seufer-Wasserthal a
Oct 12, 2022 07:00 am ET
WILLOW BIOSCIENCES ANNOUNCES NEW FUNCTIONAL INGREDIENT ASTAXANTHIN ADDED TO PRODUCT PORTFOLIO
CALGARY, AB and MOUNTAIN VIEW, Calif., Oct. 12, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce that it has completed proof of concept work, and has started yeast strain optimization and process development toward commercial production of astaxanthin, a powerful, naturally occurring, antioxidant compound that is used in diverse industries such as animal feed, food & nutrition, an
Oct 12, 2022 07:00 am ET
WILLOW BIOSCIENCES ANNOUNCES NEW FUNCTIONAL INGREDIENT ASTAXANTHIN ADDED TO PRODUCT PORTFOLIO
CALGARY, AB and MOUNTAIN VIEW, Calif., Oct. 12, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce that it has completed proof of concept work, and has started yeast strain optimization and process development toward commercial production of astaxanthin, a powerful, naturally occurring, antioxidant compound that is used in diverse industries such as animal feed, food & nutrit
Aug 31, 2022 07:00 am ET
WILLOW BIOSCIENCES PROVIDES CBG UPDATE
CALGARY, AB and MOUNTAIN VIEW, Calif, Aug. 31, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to provide an update on cannabigerol ("CBG"), the Company's first commercialized functional ingredient in its portfolio.
Aug 31, 2022 07:00 am ET
WILLOW BIOSCIENCES PROVIDES CBG UPDATE
CALGARY, AB and MOUNTAIN VIEW, Calif, Aug. 31, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to provide an update on cannabigerol ("CBG"), the Company's first commercialized functional ingredient in its portfolio.
Aug 15, 2022 07:00 am ET
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2022 RESULTS
CALGARY, AB AND MOUNTAIN VIEW, CA, Aug. 15, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, has released its financial and operating results for the three months ended June 30, 2022, reporting significant progress to its operational platform, leadership and strong liquidity.
Aug 15, 2022 07:00 am ET
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2022 RESULTS
CALGARY, AB AND MOUNTAIN VIEW, CA, Aug. 15, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, has released its financial and operating results for the three months ended June 30, 2022, reporting significant progress to its operational platform, leadership and strong liquidity.
Jul 18, 2022 07:00 am ET
WILLOW BIOSCIENCES APPOINTS DR. PETER SEUFER-WASSERTHAL AS INTERIM PRESIDENT AND CEO
CALGARY, AB and MOUNTAIN VIEW, Calif. , July 18, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, is pleased to announce that the Board of Directors has appointed Dr. Peter Seufer-Wasserthal as Interim President and Chief Executive Officer, effective July 17, 2022, in connection with Trevor Peters' retirement as President and CEO. Mr. Peters will continue to be a Director of the Company. In addition to the above menti
Jul 18, 2022 07:00 am ET
WILLOW BIOSCIENCES APPOINTS DR. PETER SEUFER-WASSERTHAL AS INTERIM PRESIDENT AND CEO
CALGARY, AB and MOUNTAIN VIEW, Calif. , July 18, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, is pleased to announce that the Board of Directors has appointed Dr. Peter Seufer-Wasserthal as Interim President and Chief Executive Officer, effective July 17, 2022, in connection with Trevor Peters' retirement as President and CEO. Mr. Peters will continue to be a Director of the Company. In addition to the abov
Jun 06, 2022 07:00 am ET
WILLOW BIOSCIENCES INCORPORATES INSCRIPTA'S ONYX® PLATFORM TO EXPAND STRAIN ENGINEERING CAPABILITIES AND THROUGHPUT
CALGARY, AB and MOUNTAIN VIEW, Calif., June 6, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients along with Inscripta®, a global leader in automated, CRISPR-based gene editing technology, announced today that Willow has incorporated the Onyx Genome Engineering Platform into its strain engineering workflows.
Jun 06, 2022 07:00 am ET
WILLOW BIOSCIENCES INCORPORATES INSCRIPTA'S ONYX® PLATFORM TO EXPAND STRAIN ENGINEERING CAPABILITIES AND THROUGHPUT
CALGARY, AB and MOUNTAIN VIEW, Calif., June 6, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients along with Inscripta®, a global leader in automated, CRISPR-based gene editing technology, announced today that Willow has incorporated the Onyx Genome Engineering Platform into its strain engineering workflows.
May 31, 2022 07:00 am ET
WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT
CALGARY, AB and MOUNTAIN VIEW, Calif., May 31, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients is pleased to announce today that is has been engaged by a specialty pharmaceutical company (the "Counterparty") to optimize an enzyme vital to the development of a large volume Active Pharmaceutical Ingredient (API) used in nutraceutical and pharmaceutical products. The Counterparty is partnered with a large-cap, multi-nat
May 31, 2022 07:00 am ET
WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT
CALGARY, AB and MOUNTAIN VIEW, Calif., May 31, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients is pleased to announce today that is has been engaged by a specialty pharmaceutical company (the "Counterparty") to optimize an enzyme vital to the development of a large volume Active Pharmaceutical Ingredient (API) used in nutraceutical and pharmaceutical products. The Counterparty is partnered with a large-cap, mu
May 13, 2022 05:48 pm ET
WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL MEETING VOTING RESULTS
VANCOUVER, BC, May 13, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general meeting of shareholders held on May 13, 2022 (the "Meeting"). A total of 42,387,564 common shares, representing approximately 34.31% of the Company's issued and outstanding shares were represented at the meeting.
May 12, 2022 06:07 pm ET
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2022 RESULTS
VANCOUVER, BC, May 12, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of high-value molecules traditionally derived from plants, has released its financial and operating results for the three months ended March 31, 2022, reporting significant progress to its operational platform and strong liquidity.
May 11, 2022 04:01 pm ET
WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS FERMENTATION MANUFACTURING NETWORK AND PROGRESS ON ITS CBG GRAS DETERMINATION
VANCOUVER, BC, May 11, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of high-value molecules traditionally derived from plants, announces expanded production capacity with a new manufacturing partnership and progress with respect to its Generally Recognized as Safe ("GRAS") determination.
May 11, 2022 04:01 pm ET
WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS FERMENTATION MANUFACTURING NETWORK AND PROGRESS ON ITS CBG GRAS DETERMINATION
VANCOUVER, BC, May 11, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of high-value molecules traditionally derived from plants, announces expanded production capacity with a new manufacturing partnership and progress with respect to its Generally Recognized as Safe ("GRAS") determination.
Mar 29, 2022 08:32 pm ET
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2021 YEAR END RESULTS, FILING OF ITS 2021 AIF, AND OPERATIONAL UPDATE
VANCOUVER, BC, March 29, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company that develops technology to manufacture pure, consistent and sustainable compounds via yeast biosynthesis, is pleased to announce its financial and operating results for the three months and year ended December 31, 2021, and filing of its Annual Information Form ("AIF"). Selected financial and operational information is outlined below and should be read with Willow's audited consolidated financial statements (the "Financial Statements") and man
Jan 31, 2022 06:00 am ET
WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST
VANCOUVER, BC, Jan. 31, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company that manufactures pure, consistent and sustainable cannabinoids via yeast biosynthesis, today announced that it will host a webcast investor presentation on Thursday, February 3rd at 2:00 PM EST.
Jan 19, 2022 06:00 am ET
WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL BENEFIT OF CBG FOR SKINCARE
VANCOUVER, BC, Jan. 19, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company that manufactures pure, consistent and sustainable cannabinoids via yeast biosynthesis, is pleased to announce the results of its in vitro analysis and the first to be reported topical clinical study on cannabigerol ("CBG"). In collaboration with Signum Biosciences, Willow's FutureGrownTM CBG, produced using its proprietary yeast platform at multi-kilogram scale, demonstrated antioxidant, anti-inflammatory, and skin health-boosting activi
Jan 19, 2022 06:00 am ET
WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL BENEFIT OF CBG FOR SKINCARE
VANCOUVER, BC, Jan. 19, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company that manufactures pure, consistent and sustainable cannabinoids via yeast biosynthesis, is pleased to announce the results of its in vitro analysis and the first to be reported topical clinical study on cannabigerol ("CBG"). In collaboration with Signum Biosciences, Willow's FutureGrownTM CBG, produced using its proprietary yeast platform at multi-kilogram scale, demonstrated antioxidant, anti-inflammatory, and skin health-boosting activity in l
Nov 15, 2021 06:00 am ET
Willow Biosciences Reports Third Quarter 2021 Results
VANCOUVER, BC, Nov. 15, 2021 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) has released its financial and operating results for the three and nine months ended September 30, 2021, reporting significant advancement in its operations and strong liquidity.
Nov 15, 2021 06:00 am ET
Willow Biosciences Reports Third Quarter 2021 Results
VANCOUVER, BC, Nov. 15, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) has released its financial and operating results for the three and nine months ended September 30, 2021, reporting significant advancement in its operations and strong liquidity.
Sep 21, 2021 07:00 am ET
Willow Biosciences Announces Commercial Scale Operational Update, CBGA Production Update and Corporate Update
VANCOUVER, BC, Sept. 21, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF), a leading biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to provide the following operational and corporate updates.
Sep 21, 2021 07:00 am ET
Willow Biosciences Announces Commercial Scale Operational Update, CBGA Production Update and Corporate Update
VANCOUVER, BC, Sept. 21, 2021 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF), a leading biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to provide the following operational and corporate updates.
Sep 20, 2021 08:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the September 16th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live executive presentations and...
Sep 13, 2021 08:35 am ET
Willow Biosciences Inc. to Webcast Live at Life Sciences Investor Forum September 16th
Willow Biosciences Inc. (TSX: WLLW, OTCQX: CANSF), based in Vancouver, Canada and is a leading biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, today announced that Trevor Peters,...
Aug 09, 2021 07:00 am ET
Willow Biosciences Reports Second Quarter 2021 Results
VANCOUVER, BC, Aug. 9, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) has released its financial and operating results for the three and six months ended June 30, 2021, reporting significant advancement in its operations and strong liquidity.
Jul 20, 2021 07:00 am ET
Willow Biosciences Announces Expansion of its Commercial Operations Team and Development Portfolio, an Update on its Intellectual Property Position, and Formation of ESG Committee
VANCOUVER, BC, July 20, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF), a leading biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to provide an update on its operations as it transitions to a production company and expands its R&D capabilities to accommodate additional development programs, including cannabinol ("CBN").
Jul 20, 2021 07:00 am ET
Willow Biosciences Announces Expansion of its Commercial Operations Team and Development Portfolio, an Update on its Intellectual Property Position, and Formation of ESG Committee
VANCOUVER, BC, July 20, 2021 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF), a leading biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to provide an update on its operations as it transitions to a production company and expands its R&D capabilities to accommodate additional development programs, including cannabinol ("CBN").
Jun 10, 2021 07:00 am ET
Willow Biosciences and Cellular Goods Announce Multiyear Supply Agreement for Cannabigerol (CBG)
VANCOUVER, BC, June 10, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF), a biotechnology company producing ultra-pure, sustainably made compounds, and Cellular Goods PLC ("Cellular Goods") (LSE: CBX), a U.K. based provider of premium consumer products based on biosynthetically made cannabinoids, are announcing today that the two companies have signed a multi-year supply agreement, whereby Willow will supply Cellular Goods with its proprietary, ultra-pure, biosynthetically produced, cannabigerol ("Willow CBG") to be used in Cellular Goods' premium c
Jun 10, 2021 07:00 am ET
Willow Biosciences and Cellular Goods Announce Multiyear Supply Agreement for Cannabigerol (CBG)
VANCOUVER, BC, June 10, 2021 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF), a biotechnology company producing ultra-pure, sustainably made compounds, and Cellular Goods PLC ("Cellular Goods") (LSE: CBX), a U.K. based provider of premium consumer products based on biosynthetically made cannabinoids, are announcing today that the two companies have signed a multi-year supply agreement, whereby Willow will supply Cellular Goods with its proprietary, ultra-pure, biosynthetically produced, cannabigerol ("Willow CBG") to be used in Cellular Goods' pr
May 25, 2021 07:00 am ET
Willow Biosciences Announces Participation In Synbiobeta Panel Discussion
VANCOUVER, BC, May 25, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF), a Canadian biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to announce that it will be presenting on a panel with other industry leaders at SynBioBeta's "Celebrating Synthetic Biology Breakthroughs in Biopharma" conference on May 26, 2021.
May 18, 2021 07:00 am ET
Willow Biosciences Added to NYSE-Listed Cannabis ETF "THCX"
VANCOUVER, BC, May 18, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF), a Canadian biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, announced today that it has been added to "the Cannabis ETF" (NYSE: THCX) ("THCX"), an exchange traded fund trading on NYSE Arca.
May 07, 2021 06:55 pm ET
Willow Biosciences Reports First Quarter 2021 Results, an Operational Update and the Addition of a New Board Member
VANCOUVER, BC, May 7, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) has released its financial and operating results for the three months ended March 31, 2021, reporting significant advancement in its operations and strong liquidity.
Apr 28, 2021 07:38 pm ET
Willow Biosciences Announces Annual General and Special Meeting Voting Results
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS./
Apr 20, 2021 07:00 am ET
Willow Biosciences Announces Ground-Breaking Scientific Data for Cannabigerol (CBG) on Human Skin
VANCOUVER, BC, April 20, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has completed a series of studies with its development partner, Signum Biosciences, Inc., that demonstrate the safety and anti-inflammatory, anti-aging, and antimicrobial properties of Willow's cannabigerol ("Willow CBG"). The studies demonstrate that Willow CBG is safe when applied to skin and eye areas and can act as a more potent antioxidant and anti-inflammatory for certain skin applications when compared to plant derived cannabidiol ("CBD"),
Mar 31, 2021 07:00 am ET
Willow Biosciences Announces Completion of its First Commercial Scale Fermentation Run
VANCOUVER, BC, March 31, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has completed the first commercial scale fermentation run of its first cannabinoid for market, cannabigerol ("CBG").
Mar 23, 2021 10:47 pm ET
Willow Biosciences Reports Fourth Quarter and 2020 Year End Results and Operational Update
CALGARY, AB, March 23, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce its financial and operating results for the three months and year ended December 31, 2020. Selected financial and operational information is outlined below and should be read with Willow's audited consolidated financial statements (the "Financial Statements") and management's discussion and analysis (the "MD&A") as of December 31, 2020, which are available on SEDAR at www.sedar.com and on Willow's website at www.willowbio.com.
Mar 03, 2021 06:00 am ET
Willow Biosciences Provides Update on Acceleration of Expiry Date of Outstanding Warrants Issued Pursuant to October 2020 Unit Financing
VANCOUVER, BC, March 3, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to provide an update on its previously announced acceleration of the expiry date of 9,320,478 common share purchase warrants (the "2020 Warrants") issued on October 29, 2020 (the "Acceleration"). The Company has completed the Acceleration, which has resulted in the issuance of approximately 9,259,404 additional common shares of the Company and cash proceeds to the Company of approximately $7.9 million. As of today, the Company had a cash balance of approximately $48.
Feb 19, 2021 10:12 am ET
Willow Biosciences Announces Exercise of Over-Allotment Option and Completion of Previously Announced Bought Deal Offering
VANCOUVER, BC, Feb. 19, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (TSX: WLLW.WT) (OTCQX: CANSF) is pleased to announce that it has closed its previously announced upsized bought deal offering of 17,424,800 common shares (the "Common Shares") of the Company at a price of $1.65 per Common Share, which includes 2,272,800 Common Shares issued pursuant to the exercise in full of the over-allotment option, for aggregate gross proceeds of approximately $28.75 million (the "Offering"). Participation in the Offering was comprised primarily of existing cornerstone sh
Feb 19, 2021 10:12 am ET
Willow Biosciences Announces Exercise of Over-Allotment Option and Completion of Previously Announced Bought Deal Offering
VANCOUVER, BC, Feb. 19, 2021 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (TSX: WLLW.WT) (OTCQX: CANSF) is pleased to announce that it has closed its previously announced upsized bought deal offering of 17,424,800 common shares (the "Common Shares") of the Company at a price of $1.65 per Common Share, which includes 2,272,800 Common Shares issued pursuant to the exercise in full of the over-allotment option, for aggregate gross proceeds of approximately $28.75 million (the "Offering"). Participation in the Offering was comprised primarily of existing corners
Feb 12, 2021 06:56 am ET
IIROC Trade Resumption - WLLW
TORONTO, Feb. 12, 2021 /CNW/ - Trading resumes in:
Feb 11, 2021 07:31 pm ET
Willow Biosciences Announces Increase to Bought Deal Offering from $20.0 Million to $25.0 Million
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; WLLW.WT; OTCQX: CANSF) is pleased to announce that in connection with its previously announced bought deal offering, Willow and the syndicate of underwriters co-led by Eight Capital...
Feb 11, 2021 03:34 pm ET
Willow Biosciences Announces $20.0 Million Bought Deal Offering
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) is pleased to announce that it has entered into an agreement with Eight Capital and BMO Capital Markets, to act as co-lead underwriters, on behalf of a syndicate of...
Feb 11, 2021 02:21 pm ET
IIROC Trading Halt - WLLW
TORONTO, Feb. 11, 2021 /CNW/ - The following issues have been halted by IIROC:
Jan 25, 2021 06:00 am ET
Willow Biosciences Announces Acceleration of Expiry Date of Outstanding Warrants Issued Pursuant to October 2020 Unit Financing
VANCOUVER, BC, Jan. 25, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (TSX: WLLW.WT) (OTCQX: CANSF) is pleased to announce that it has elected to exercise its right under the terms of a warrant indenture dated October 29, 2020 (the "Warrant Indenture") governing the common share purchase warrants of the Company issued on October 29, 2020 (the "2020 Warrants") to accelerate the expiry date of the 2020 Warrants.
Jan 25, 2021 06:00 am ET
Willow Biosciences Announces Acceleration of Expiry Date of Outstanding Warrants Issued Pursuant to October 2020 Unit Financing
VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (TSX: WLLW.WT) (OTCQX: CANSF) is pleased to announce that it has elected to exercise its right under the terms of a warrant indenture dated October 29, 2020 (the "Warrant Indenture") governing the common share purchase warrants of the Company issued on October 29, 2020 (the "2020 Warrants") to accelerate the expiry date of the 2020 Warrants.
Jan 19, 2021 06:00 am ET
Willow Biosciences Advances Its Work On THC; Plans To Launch In The Canadian Market
VANCOUVER, BC, Jan. 19, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has advanced its work on its proprietary yeast strain for production of Tetrahydrocannabinol ("THC"), and plans to commercially launch in the Canadian market.
Jan 19, 2021 06:00 am ET
Willow Biosciences Advances Its Work On THC; Plans To Launch In The Canadian Market
VANCOUVER, BC, Jan. 19, 2021 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has advanced its work on its proprietary yeast strain for production of Tetrahydrocannabinol ("THC"), and plans to commercially launch in the Canadian market.
Jan 13, 2021 06:00 am ET
Willow Biosciences Provides Update on Cannabigerol Research Studies and Key Personnel Appointment
VANCOUVER, BC, Jan. 13, 2021 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it is undertaking two initiatives to help our customers evaluate and better understand cannabigerol ("CBG"), our first commercial cannabinoid slated for production in Q1 2021.
Jan 13, 2021 06:00 am ET
Willow Biosciences Provides Update on Cannabigerol Research Studies and Key Personnel Appointment
VANCOUVER, BC, Jan. 13, 2021 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it is undertaking two initiatives to help our customers evaluate and better understand cannabigerol ("CBG"), our first commercial cannabinoid slated for production in Q1 2021.
Dec 16, 2020 06:00 am ET
Willow Biosciences Advances its Commericalization Plan; First Commercial Production Expected in Early 2021
Leading manufacturer contracted for commercial cannabinoid production First commercial quantities of ultra-pure CBG expected to be produced in Q1 2021 First revenue generation expected in Q2 2021, six months ahead of initial expectations VANCOUVER, BC, Dec. 16, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has advanced its commercialization plan by selecting a highly-regarded contract manufacturing organization ("CMO") to manufacture its first cannabinoid, cannabigerol ("CBG"), with its first commercial scale mult
Dec 16, 2020 06:00 am ET
Willow Biosciences Advances its Commericalization Plan; First Commercial Production Expected in Early 2021
Leading manufacturer contracted for commercial cannabinoid production First commercial quantities of ultra-pure CBG expected to be produced in Q1 2021 First revenue generation expected in Q2 2021, six months ahead of initial expectations VANCOUVER, BC, Dec. 16, 2020 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has advanced its commercialization plan by selecting a highly-regarded contract manufacturing organization ("CMO") to manufacture its first cannabinoid, cannabigerol ("CBG"), with its first commercial sca
Nov 12, 2020 08:36 pm ET
Willow Biosciences Reports Third Quarter 2020 Results and Operational Update
CALGARY, AB, Nov. 12, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) has released its financial and operating results for the three and nine months ended September 30, 2020, reporting significant advancement in its operations and strong liquidity.
Nov 12, 2020 08:36 pm ET
Willow Biosciences Reports Third Quarter 2020 Results and Operational Update
CALGARY, AB, Nov. 12, 2020 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) has released its financial and operating results for the three and nine months ended September 30, 2020, reporting significant advancement in its operations and strong liquidity.
Oct 29, 2020 09:26 am ET
Willow Biosciences Announces Exercise of Over-Allotment Option and Completion of Previously Announced Public Offering
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has closed its previously announced upsized public offering of 17,692,307 units ("Units") of the Company at a price of $0.65 per Unit, which includes 2,307,692 Units issued pursuant to the exercise in full of the over-allotment option, for aggregate gross proceeds of approximately $11.5 million (the "Offering").
Oct 21, 2020 09:14 am ET
IIROC Trade Resumption - WLLW
TORONTO, Oct. 21, 2020 /CNW/ - Trading resumes in:
Oct 21, 2020 08:29 am ET
Willow Biosciences Announces Pricing and Upsize of Previously Announced Public Offering to $10.0 Million
/NOT FOR DISTRIBUTION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW./
Oct 20, 2020 03:51 pm ET
Willow Biosciences Announces Overnight Marketed Public Offering for Proceeds of Approximately $8.0 Million
/NOT FOR DISTRIBUTION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW./
Oct 20, 2020 03:37 pm ET
IIROC Trading Halt - WLLW
TORONTO, Oct. 20, 2020 /CNW/ - The following issues have been halted by IIROC:
Oct 08, 2020 06:00 am ET
Willow Biosciences Partners with Researchers at the University of Lethbridge and University of Calgary to Study Effects Of Non-Psychoactive Cannabinoids on Pain, Inflammation and Depression
VANCOUVER, BC, Oct. 8, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has agreed to partner with researchers at the University of Lethbridge and the University of Calgary to study the therapeutic potential of non-psychoactive cannabinoids in relation to intestinal inflammation, abdominal pain and depression. These studies are financially supported by Alberta Innovates and involve laboratory testing in preclinical models of disease. To support the research, Willow will be providing four different, non-plant derived c
Sep 21, 2020 08:35 am ET
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the September 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and...
Sep 21, 2020 08:00 am ET
Willow Biosciences announces successful production of pure cannabigerol
VANCOUVER, BC, Sept 21, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has successfully developed a scalable process for producing cannabigerol ("CBG") with greater than 99% purity and no detectable THC and demonstrated production at 500 litre scale.
Sep 14, 2020 08:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Sep 14, 2020 08:30 am ET
Willow Biosciences Inc. to Webcast Live at Life Sciences Investor Forum September 17th
Willow Biosciences Inc. (TSX: WLLW, OTCQX: CANSF), based in Vancouver, Canada, focused on manufacturing pharmaceutical grade quality cannabinoids via synthetic biology, today announced that Trevor Peters, President and Chief Executive Officer, will...
Sep 08, 2020 08:00 am ET
Willow Biosciences Announces Research and Development Funding for its Varin Cannabinoids
VANCOUVER, BC, Sept. 8, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW); (OTCQX: CANSF) is pleased to announce that its subsidiary - Willow Analytics Inc. - will receive advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program ("NRC IRAP") supporting a research and development project to advance production of its varin cannabinoids, using its proprietary biosynthetic platform.
Aug 12, 2020 07:04 pm ET
Willow Biosciences Reports Second Quarter 2020 Results and Operational Update
CALGARY, AB, Aug. 12, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) has released its financial and operating results for the three and six months ended June 30, 2020, reporting significant advancement in its operations and strong liquidity.
Jul 29, 2020 08:00 am ET
Willow Biosciences Announces It Has Commenced Its Pilot to Produce Its First Cannabinoid
VANCOUVER, BC, July 29, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has commenced its 500 liter pilot production run to deliver samples of its first cannabinoid, cannabigerol ("CBG"), in Q3 of 2020.
Jul 22, 2020 08:00 am ET
Willow Biosciences to Commence Trading on The OTCQX® Best Market
VANCOUVER, BC, July 22, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has been approved to commence trading on the OTCQX® Best Market (the "OTCQX"), beginning today, July 22, 2020, under the symbol "CANSF". Willow has upgraded to the OTCQX from the OTCQB® Venture Market (the "OTCQB"). U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.
Jul 22, 2020 07:00 am ET
OTC Markets Group Welcomes Willow Biosciences Inc. to OTCQX
NEW YORK, July 22, 2020 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF), a Canadian biotechnology company, has qualified to trade on the OTCQX® Best Market. Willow Biosciences Inc. upgraded to OTCQX from the OTCQB® Venture Market.
Jul 10, 2020 08:35 am ET
Cannabis & CBD Biopharma Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Jul 10, 2020 08:35 am ET
Cannabis & CBD Biopharma Investor Presentations Now Available for On-Demand Viewing
NEW YORK, July 10, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the Cannabis & CBD Biopharma Virtual lnvestor Conference presentations are now available for on-demand viewing.
Jul 07, 2020 03:00 pm ET
Live Investor Conference & Webinar: Cannabis & CBD Biopharma Industry Companies Present July 9th
Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com
Jul 07, 2020 03:00 pm ET
Live Investor Conference & Webinar: Cannabis & CBD Biopharma Industry Companies Present July 9th
NEW YORK, July 7, 2020 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Cannabis & CBD Industry Virtual Investor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 10:15 AM ET, with the first live webcast at 10:30 AM ET, on Thursday, July 9th.
Jul 06, 2020 08:35 am ET
Willow Biosciences Inc. to Webcast Live at VirtualInvestorConferences.com July 9th
VANCOUVER, BC, July 6, 2020 /PRNewswire/ -- Willow Biosciences Inc. (TSX: WLLW, OTCQB: CANSF), based in Vancouver, Canada, focused on manufacturing pharmaceutical grade quality cannabinoids via synthetic biology, today announced that Trevor Peters, President and Chief Executive Officer, will present live at VirtualInvestorConferences.com on July 9th.
Jun 22, 2020 06:52 pm ET
Willow Biosciences Announces Appointment of Senior Vice President, Sales and Marketing
CALGARY, AB, June 22, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce that Christopher Speed has joined the Company as Senior Vice President, Sales and Marketing, effective July 1, 2020. In this role, Mr. Speed will lead the sales and marketing of Willow's new line of cannabinoids, along with the Company's strategic planning and customer initiatives.
Jun 17, 2020 08:00 am ET
Willow Biosciences Announces Expedited Pilot Production and Adds Multiple New Cannabinoids to Portfolio
CALGARY, AB, June 17, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce that it has further accelerated its path to commercialization following continued scale-up development success and the addition of multiple new cannabinoids for production. Willow is a Canadian biotechnology company creating high purity, plant-derived compounds for the global pharmaceutical, health and wellness and consumer packaged goods industries.
Jun 17, 2020 08:00 am ET
Willow Biosciences Announces Expedited Pilot Production and Adds Multiple New Cannabinoids to Portfolio
CALGARY, AB, June 17, 2020 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce that it has further accelerated its path to commercialization following continued scale-up development success and the addition of multiple new cannabinoids for production. Willow is a Canadian biotechnology company creating high purity, plant-derived compounds for the global pharmaceutical, health and wellness and consumer packaged goods industries.
Jun 01, 2020 05:55 pm ET
Willow Biosciences Announces Annual General And Special Meeting Voting Results
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS/
May 14, 2020 07:24 pm ET
Willow Biosciences Reports First Quarter 2020 Results And Operational Update
CALGARY, May 14, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF) has released its financial and operating results for the three months ended March 31, 2020.
May 14, 2020 07:24 pm ET
Willow Biosciences Reports First Quarter 2020 Results And Operational Update
CALGARY, May 14, 2020 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF) has released its financial and operating results for the three months ended March 31, 2020.
Apr 07, 2020 07:46 pm ET
Willow Biosciences Announces Changes to its Management Team
CALGARY, April 7, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or "the Company") (TSX: WLLW; OTCQB: CANSF) announces changes to its management team with the promotion of Dr. Chris Savile to Chief Operations Officer and the departure of Dr. Peter Facchini, Chief Scientific Officer, and Dr. Jill Hagel, Vice President, Applied Science, effective immediately.
Apr 07, 2020 07:46 pm ET
Willow Biosciences Announces Changes to its Management Team
CALGARY, April 7, 2020 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or "the Company") (TSX: WLLW; OTCQB: CANSF) announces changes to its management team with the promotion of Dr. Chris Savile to Chief Operations Officer and the departure of Dr. Peter Facchini, Chief Scientific Officer, and Dr. Jill Hagel, Vice President, Applied Science, effective immediately.
Mar 24, 2020 09:22 pm ET
Willow Biosciences Reports Fourth Quarter and 2019 Year End Results and Operational Update
CALGARY, March 24, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF) is pleased to announce its financial and operating results for the three months and year ended December 31, 2019. Selected financial and operational information is outlined below and should be read with Willow's audited consolidated financial statements (the "Financial Statements") and management's discussion and analysis (the "MD&A") as of December 31, 2019, which are available on SEDAR at www.sedar.com and on Willow's website at www.willowbio.com. The Company's annual informati
Mar 24, 2020 09:22 pm ET
Willow Biosciences Reports Fourth Quarter and 2019 Year End Results and Operational Update
CALGARY, March 24, 2020 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF) is pleased to announce its financial and operating results for the three months and year ended December 31, 2019. Selected financial and operational information is outlined below and should be read with Willow's audited consolidated financial statements (the "Financial Statements") and management's discussion and analysis (the "MD&A") as of December 31, 2019, which are available on SEDAR at www.sedar.com and on Willow's website at www.willowbio.com. The Company's annual in
Mar 12, 2020 08:00 am ET
Willow Biosciences Announces Cannabinoid Scale-Up and Expedited Path to Commercialization
CALGARY, March 12, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or "the Company") (TSX: WLLW; OTCQB: CANSF), is pleased to announce that it has achieved its first major commercial milestone by delivering a proprietary cannabinoid-producing yeast strain to its scale-up development partner, Albany Molecular Research, Inc. ("AMRI") to begin the process of scaling up production to commercial volumes.
Feb 07, 2020 06:30 am ET
Willow Biosciences Improves Governance with Appointment of Independent Chairman
CALGARY, Feb. 7, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF) is pleased to announce that it has appointed Dr. Peter Seufer-Wasserthal as independent Chairman of the Board of Directors and Dr. Joseph Tucker as Chief Operating Officer of Willow.
Jan 15, 2020 01:35 pm ET
Willow Biosciences Inc. Opens the Market
TORONTO, Jan. 15, 2020 /CNW/ - Trevor Peters, President, Chief Executive Officer and Director, Willow Biosciences Inc. (WLLW), joined Dani Lipkin, Innovation Sector Head, Capital Formation, Toronto Stock Exchange and TSX Venture Exchange, to open the market. Willow is a Canadian biotechnology company based in Calgary, Alberta, that produces high purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow Biosciences Inc. commenced trading on Toronto Stock Exchange on December 5, 2019.
Dec 03, 2019 04:04 pm ET
Willow Biosciences Announces Trading Date on the Toronto Stock Exchange
CALGARY, Dec. 3, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW; OTCQB: CANSF) announces that it has received final approval from the Toronto Stock Exchange (the "TSX") to list its common shares (the "Common Shares") on the TSX.
Dec 03, 2019 06:30 am ET
Willow Biosciences Comments on Descheduling of Partner's Cannabidiol by U.S. Drug Enforcement Agency
CALGARY, Dec. 3, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW; OTCQB: CANSF), a Canadian biotechnology company and a leading developer in biosynthetically produced cannabidiol ("CBD"), comments on Purisys, LLC's ("Purisys") news release issued on November 21st stating that the U.S. Drug Enforcement Agency (the "DEA") has removed Purisys' CBD from Schedule I of the Controlled Substances Act (the "CSA"). Purisys is the spin-out entity of Noramco, Inc.'s ("Noramco") industry-leading cannabinoids business, which began to operate as a stand-alone entity from Noramc
Nov 25, 2019 07:00 am ET
Willow Biosciences Receives Conditional Approval to List on the Toronto Stock Exchange
CALGARY, Nov. 25, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW; OTCQB: CANSF) announces that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to list its common shares (the "Common Shares") on the TSX.
Nov 21, 2019 07:31 pm ET
Willow Biosciences Reports Third Quarter 2019 Results and Provides Operations Update
CALGARY, Nov. 21, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW, OTCQB: CANSF) has released its financial and operating results for the three and nine months ended September 30, 2019.
Nov 07, 2019 06:30 am ET
Willow Biosciences to Participate in Cowen 2nd Annual Boston Cannabis Conference
CALGARY, Nov. 7, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW; OTCQB: CANSF) announces that it will participate in the Cowen 2nd Annual Boston Cannabis Conference being held on November 12th and 13th, 2019, at the InterContinental Boston.
Nov 07, 2019 06:30 am ET
Willow Biosciences to Participate in Cowen 2nd Annual Boston Cannabis Conference
CALGARY, Nov. 7, 2019 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW; OTCQB: CANSF) announces that it will participate in the Cowen 2nd Annual Boston Cannabis Conference being held on November 12th and 13th, 2019, at the InterContinental Boston.
Nov 05, 2019 06:30 am ET
Willow Biosciences to Commence Trading on the OTCQB® Venture Market
CALGARY, Nov. 5, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE:WLLW; OTCQB:CANSF) is pleased to announce that it has been approved to commence trading on The OTCQB® Venture Market (the "OTCQB"), beginning today, November 5, 2019, under the symbol "CANSF". This U.S. listing will provide the Company with access to a broader base of U.S. and international retail and institutional investors, ultimately providing investors with increased access to data, transparency and liquidity. Quotes for Willow's U.S. symbol will be available once the Company's stock commences trading
Nov 05, 2019 06:30 am ET
Willow Biosciences to Commence Trading on the OTCQB® Venture Market
CALGARY, Nov. 5, 2019 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE:WLLW; OTCQB:CANSF) is pleased to announce that it has been approved to commence trading on The OTCQB® Venture Market (the "OTCQB"), beginning today, November 5, 2019, under the symbol "CANSF". This U.S. listing will provide the Company with access to a broader base of U.S. and international retail and institutional investors, ultimately providing investors with increased access to data, transparency and liquidity. Quotes for Willow's U.S. symbol will be available once the Company's stock commences t
Sep 17, 2019 08:30 am ET
Willow Biosciences to Participate at the Eight Capital & Cassels Brock Global Cannabis Conference
CALGARY, Sept. 17, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE:WLLW) announces that it will participate in a panel, and will be available for 1x1 meetings, at the Eight Capital & Cassels Brock Global Cannabis Conference being held on September 19, 2019, at the Shangri-La Hotel in Toronto.
Sep 17, 2019 08:30 am ET
Willow Biosciences to Participate at the Eight Capital & Cassels Brock Global Cannabis Conference
CALGARY, Sept. 17, 2019 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE:WLLW) announces that it will participate in a panel, and will be available for 1x1 meetings, at the Eight Capital & Cassels Brock Global Cannabis Conference being held on September 19, 2019, at the Shangri-La Hotel in Toronto.
Sep 09, 2019 09:08 pm ET
Willow Biosciences Announces Stock Option Grant and Issuance of Units
CALGARY, Sept. 9, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW) announces that, pursuant to the terms and conditions of its stock option plan, it has granted an aggregate of 1,118,000 stock options ("Options") to purchase common shares ("Common Shares") of Willow to certain employees. The Options expire five years from the date of grant and are exercisable at a price of $0.60 per Common Share. The Options vest as to one third on the grant date and one third on each of the first and second anniversaries of the grant date.
Sep 09, 2019 09:08 pm ET
Willow Biosciences Announces Stock Option Grant and Issuance of Units
CALGARY, Sept. 9, 2019 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW) announces that, pursuant to the terms and conditions of its stock option plan, it has granted an aggregate of 1,118,000 stock options ("Options") to purchase common shares ("Common Shares") of Willow to certain employees. The Options expire five years from the date of grant and are exercisable at a price of $0.60 per Common Share. The Options vest as to one third on the grant date and one third on each of the first and second anniversaries of the grant date.
Sep 03, 2019 05:56 pm ET
Willow Biosciences Announces Engagement of The Howard Group and Upcoming Presentation at the 8th Annual Gateway Conference on September 5, 2019
CALGARY, Sept. 3, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE:WLLW) is pleased to announce it has engaged The Howard Group as its capital markets communications advisor to assist with both traditional and online initiatives targeting institutional and retail investing groups as well as the larger investment community.
Sep 03, 2019 05:56 pm ET
Willow Biosciences Announces Engagement of The Howard Group and Upcoming Presentation at the 8th Annual Gateway Conference on September 5, 2019
CALGARY, Sept. 3, 2019 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE:WLLW) is pleased to announce it has engaged The Howard Group as its capital markets communications advisor to assist with both traditional and online initiatives targeting institutional and retail investing groups as well as the larger investment community.
Aug 30, 2019 12:20 pm ET
Willow Biosciences Reports Second Quarter 2019 Results and Provides Operations Update
CALGARY, Aug. 30, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW) has released its financial and operating results for the three and six months ended June 30, 2019. Selected financial and operational information is outlined below and should be read in conjunction with Willow's unaudited condensed consolidated interim financial statements for the three and six months ended June 30, 2019 and related management's discussion and analysis which are available on SEDAR at www.sedar.com.
Aug 30, 2019 12:20 pm ET
Willow Biosciences Reports Second Quarter 2019 Results and Provides Operations Update
CALGARY, Aug. 30, 2019 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW) has released its financial and operating results for the three and six months ended June 30, 2019. Selected financial and operational information is outlined below and should be read in conjunction with Willow's unaudited condensed consolidated interim financial statements for the three and six months ended June 30, 2019 and related management's discussion and analysis which are available on SEDAR at www.sedar.com.
Jul 22, 2019 08:30 am ET
Synthetic Cannabinoids: The New Age of Medical Marijuana-- CFN Media
Seattle, Washington--(Newsfile Corp. - July 22, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces the publication of an article covering Willow Biosciences (CSE: WLLW) (OTC: CANSF) and the fascinating world of biosynthetically produced cannabinoids.
Jul 11, 2019 05:16 pm ET
Willow Biosciences Comments on Share Price Activity
CALGARY, July 11, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW), at the request of IIROC on behalf of the Canadian Securities Exchange, announces that it is not aware of any material facts or changes in respect of the business of the Company which would result in a significant change in the trading price and volume of the common shares of the Company.
Jun 18, 2019 08:40 am ET
Betting Big on the New Age of Synthetic Cannabinoids - CFN Media
Seattle, Washington--(Newsfile Corp. - June 18, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Willow Biosciences (CSE: WLLW) and its next-generation cannabis manufacturing process.
Jun 05, 2019 09:00 am ET
InvestmentPitch Media Video Discusses Willow Biosciences' Joint Development Agreement with Noramco to Develop Yeast-Based Biosynthesis Platform for Production and Distribution of CBD - Video Available
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2019) - Willow Biosciences (CSE: WLLW) and Noramco, Inc. have entered into an exclusive Joint Development Agreement to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of CBD. As a technology platform, biosynthesis can provide a low-cost, ultra-pure and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.
Jun 04, 2019 07:00 am ET
Willow Biosciences and Noramco Announce Joint Development of Biosynthesis Platform for Cannabidiol
New activity will add options and potential for cost savings to Noramco's robust CBD platform in support of emerging markets
May 30, 2019 08:30 am ET
Willow Biosciences: The Science of Industrial Scale Pharmaceutical Cannabinoid Production -- CFN Media
Seattle, Washington--(Newsfile Corp. - May 30, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Willow Biosciences Inc. (CSE: WLLW) and its unique take on cannabis production.
May 27, 2019 05:00 pm ET
Willow Biosciences and Tuatara Capital Announce Exercise of Warrants
CALGARY, May 27, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW) and Tuatara Capital Fund II, L.P. ("Tuatara") are pleased to announce that Tuatara has acquired 9,219,390 common shares ("Common Shares") of the Company pursuant to the exercise of Common Share purchase warrants ("Warrants") for proceeds to the Company of $8,066,966.67 (the "Warrant Exercise").
May 17, 2019 11:04 am ET
IIROC Trade Resumption - WLLW
VANCOUVER, May 17, 2019 /CNW/ - Trading resumes in:
May 17, 2019 09:40 am ET
IIROC Trading Halt - WLLW
VANCOUVER, May 17, 2019 /CNW/ - The following issues have been halted by IIROC:
May 14, 2019 08:00 am ET
Willow Biosciences Inc. Announces Share Consolidation
CALGARY, May 14, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW) announces that it will be consolidating all of the issued and outstanding common shares of the Company ("Common Shares") on the basis of one (1) post‐consolidation Common Share for each twenty-five (25) pre‐consolidation Common Shares (the "Consolidation").
May 02, 2019 08:00 am ET
Willow Biosciences Inc. Announces Appointment of Vice President, Corporate Development, Stock Option Grant and Investor Presentation
CALGARY, May 2, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW) is pleased to announce that Troy Talkkari has joined the Company as Vice President, Corporate Development, effective May 1, 2019.
Apr 16, 2019 09:10 am ET
CSE New Listing - Willow Biosciences Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - April 16, 2019) - Willow Biosciences (CSE: WLLW) is one of the latest new listing on the Canadian Securities Exchange, having previously traded as Makena Resources, prior to a fundamental change of business. By combining with BioCan Technologies and Epimeron, Willow brings together world-leading discovery biologists and business experts in Canada and the United States to advance BioCan's current biosynthesis platform.
Apr 12, 2019 10:18 pm ET
Makena Resources Inc., Biocan Technologies Inc. and Epimeron Inc. Announce Completion of Private Placement, Strategic Investment From Tuatara Capital and Business Combination to Form Willow Bioscience
/NOT FOR DISTRIBUTION OR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW./
Apr 12, 2019 04:39 pm ET
IIROC Trade Resumption - WLLW
VANCOUVER, April 12, 2019 /CNW/ - Trading resumes in:
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
